Thermo Fisher Scientific Inc. $TMO Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 538,524 shares of the medical research company’s stock after selling 96,304 shares during the period. Thermo Fisher Scientific accounts for 0.8% of Handelsbanken Fonder AB’s portfolio, making the stock its 19th largest position. Handelsbanken Fonder AB’s holdings in Thermo Fisher Scientific were worth $269,994,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. Salomon & Ludwin LLC raised its position in shares of Thermo Fisher Scientific by 1.6% in the 4th quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock worth $669,000 after buying an additional 17 shares during the period. Elyxium Wealth LLC grew its position in Thermo Fisher Scientific by 1.9% during the fourth quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock valued at $613,000 after acquiring an additional 20 shares during the period. Revolve Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the period. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. lifted its stake in shares of Thermo Fisher Scientific by 0.7% in the 3rd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock valued at $1,436,000 after purchasing an additional 20 shares in the last quarter. Finally, Bridgewater Advisors Inc. lifted its position in Thermo Fisher Scientific by 0.9% during the fourth quarter. Bridgewater Advisors Inc. now owns 2,410 shares of the medical research company’s stock valued at $1,534,000 after buying an additional 22 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Up 0.8%

Shares of NYSE TMO opened at $598.68 on Tuesday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The stock’s 50 day moving average price is $519.74 and its two-hundred day moving average price is $509.70. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99. The stock has a market capitalization of $221.36 billion, a P/E ratio of 32.20, a PEG ratio of 2.42 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the previous year, the business earned $4.28 EPS. The business’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Analyst Upgrades and Downgrades

TMO has been the subject of several recent research reports. HSBC lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Morgan Stanley increased their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Sanford C. Bernstein initiated coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They set a “market perform” rating and a $520.00 price objective on the stock. Evercore set a $570.00 target price on Thermo Fisher Scientific in a research note on Monday, July 6th. Finally, Royal Bank Of Canada raised their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares of the company’s stock, valued at $13,927,815. This trade represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 26,553 shares of company stock valued at $15,343,589. Corporate insiders own 0.33% of the company’s stock.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher received FDA clearance for a multiple myeloma testing platform, strengthening its position in clinical diagnostics and potentially expanding adoption among hospitals, laboratories, and pharmaceutical companies. The development reinforces the company’s broader growth strategy in precision medicine. How Investors Are Reacting To Thermo Fisher Scientific New FDA-Cleared Multiple Myeloma Platform
• Positive Sentiment: Thermo Fisher expects its India customer base to grow 15% to 20% over the next five years as biopharmaceutical research and manufacturing expand in the country. The outlook points to a meaningful long-term international growth opportunity for the company’s instruments, services, and bioproduction businesses. Thermo Fisher Eyes India Customer Growth
• Positive Sentiment: Comparative coverage emphasizes Thermo Fisher’s stronger recent positioning in a potential recovery of pharmaceutical and biotechnology research spending. The company exceeded second-quarter expectations, raised guidance, and reported broad-based demand improvement, factors that can support investor confidence relative to peers such as Danaher. Thermo Fisher vs. Danaher
• Neutral Sentiment: Articles comparing Thermo Fisher with Abbott and Azenta frame the investment decision around diversification, valuation, and exposure to a life-sciences spending recovery. These are investor-perspective pieces rather than new company announcements, so their direct effect on TMO is limited. Abbott vs. Thermo Fisher Thermo Fisher and Azenta Comparison
• Negative Sentiment: CEO Marc Casper and Chief Accounting Officer Joseph Holmes sold shares. Both transactions were disclosed as part of planned trading activity, reducing the likelihood that the sales signal deteriorating business prospects, but insider selling can still create modest short-term sentiment pressure. Thermo Fisher Insider Trading Filing

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.